| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | 0.07 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |